Effects of unkei-to, an herbal medicine, on endocrine function and ovulation in women with high basal levels of luteinizing hormone secretion.
OBJECTIVE
To treat anovulatory women with high plasma LH levels with unkei-to.


METHODS
A total of 100 patients with polycystic ovary syndrome (n = 38) or non-polycystic ovary syndrome (n = 62) were allocated randomly into two groups. Endocrine levels (FSH, LH and estradiol), follicle growth and response to unkei-to were compared for 52 subjects in the unkei-to group and 48 subjects in the control group.


RESULTS
Unkei-to induced significant decreases in plasma LH in polycystic ovary syndrome and non-polycystic ovary syndrome with high LH levels. Plasma estradiol levels increased significantly (43.5%) in eight weeks of treatment with unkei-to. Significant development of the dominant follicle was also observed in patients treated with unkei-to. When women suffering from ovulatory failure or irregular menstruation and having high plasma LH concentration were treated with unkei-to for eight weeks, a reduction in the serum LH level of at least 1 SD from baseline was noted in 45.5% of polycystic ovary syndrome patients and in 80.0% of non-polycystic ovary syndrome patients. The mean rate of reduction of serum LH was 22.2 +/- 35.7% in polycystic ovary syndrome patients and 49.7 +/- 15.3% in non-polycystic ovary syndrome patients. This reduction was significant in the non-polycystic ovary syndrome patients (P = .030). The rate of menstrual cycle improvement, including successful ovulation, was 50.0% in the polycystic ovary syndrome group and 60.0% in the non-polycystic ovary syndrome group, with no significant difference between the two groups.
Ushiroyama
T
T
Department of Obstetrics and Gynecology, Osaka Medical College, 2-7 Daigaku-machi, Takatsuki, Osaka 569-8686, Japan. gyn003@poh.osaka-med.ac.jp
Ikeda
A
A
Sakai
M
M
Hosotani
T
T
Suzuki
Y
Y
Tsubokura
S
S
Ueki
M
M
D000328:Adult; D000858:Anovulation / Q000188:drug therapy / Q000209:etiology; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D004702:Endocrine Glands / Q000503:physiopathology*; D004958:Estradiol / Q000097:blood; D005260:Female; D005640:Follicle Stimulating Hormone / Q000097:blood; D006801:Humans; D007986:Luteinizing Hormone / Q000097:blood / Q000378:metabolism*; D008599:Menstruation Disturbances / Q000188:drug therapy / Q000209:etiology; D010060:Ovulation; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology*
D004365:Drugs, Chinese Herbal; C058415:unkei-to; D004958:Estradiol; D007986:Luteinizing Hormone; D005640:Follicle Stimulating Hormone